Pharmacological Actions of Cannabinoids 49Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG (1998) Comparison of
cannabinoid binding sites in guinea-pig forebrain and small intestine. Br J Pharmacol
125:1345–1351
RossRA,BrockieHC,StevensonLA,MurphyVL,TempletonF,MakriyannisA,PertweeRG
(1999a) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors
of L759633, L759656 and AM630. Br J Pharmacol 126:665–672
Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG (1999b)
Structural determinants of the partial agonist-inverse agonist properties of 6’-azidohex-
2’-yne-∆8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128:735–743
Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG
(2001) Structure-activity relationship for the endogenous cannabinoid, anandamide,
and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Br J Pharmacol 132:631–640
Rubovitch V, Gafni M, Sarne Y (2002) The cannabinoid agonist DALN positively modulates
L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Mol Brain
Res 101:93–102
Ruiu S, Pinna GA, Marchese G, Mussinu J-M, Saba P, Tambaro S, Casti P, Vargiu R, Pani L
(2003) Synthesis and characterization of NESS 0327: a novel putative antagonist of the
CB1 cannabinoid receptor. J Pharmacol Exp Ther 306:363–370
Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-
arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent
G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664–672
Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT (2003) An optimized approach
to study endocannabinoid signaling: evidence against constitutive activity of rat brain
adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451–1459
Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabi-
noid receptors. Trends Pharmacol Sci 22:565–572
Schlicker E, Redmer A, Werner A, Kathmann M (2003) Lack of CB1 receptors increases
noradrenaline release in vas deferens without affecting atrial noradrenaline release or
cortical acetylcholine. Br J Pharmacol 140:323–328
SelleyDE,StarkS,SimLJ,ChildersSR(1996)Cannabinoidreceptorstimulationofguanosine-
5’-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci 59:659–668
Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for
binding of anandamide-type compounds to the brain cannabinoid receptor. J Med
Chem 40:659–667
Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara
P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from
alternative splicing. J Biol Chem 270:3726–3731
Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, Le Fur
G, Caput D, Ferrara P (1996) Molecular cloning, expression and function of the murine
CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307:132–136
Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a trans-
fected cell line expressing a peripheral cannabinoid receptor (CB2): identification of
cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999
Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of receptor-activated G pro-
teins in rat brain by agonist-stimulated guanylyl 5’-[γ-[35S]thio]triphosphate binding.
Proc Natl Acad Sci USA 92:7242–7246
Sim-Selley LJ, Brunk LK, Selley DE (2001) Inhibitory effects of SR141716A on G-protein
activation in rat brain. Eur J Pharmacol 414:135–143
Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A,
Malan TP (2001) The cannabinoid agonist WIN55,212-2 suppresses opioid-induced
emesis in ferrets. Anesthesiology 94:882–887